Outcomes Study: Evaluating the Impact of Health-System Specialty Pharmacy Services on Dermatology Life Quality Index (DLQI) in the Treatment of Plaque Psoriasis

All Posts

Outcomes Study: Evaluating the Impact of Health-System Specialty Pharmacy Services on Dermatology Life Quality Index (DLQI) in the Treatment of Plaque Psoriasis

Background

  • Plaque psoriasis, the most common clinical type of psoriasis, typically presents with large oval circular plaques over the scalp, trunk and joint surfaces. About 2% of the United States population suffers from this condition.
  • The Dermatology Life Quality Index (DLQI) score is a patient-reported quality-of-life assessment tool used for several dermatologic conditions. Collection of this score is often a gap in care in this patient population.
  • A small study has shown that clinical pharmacists can improve overall adherence in psoriasis patients; however, there currently are no studies quantifying the impact of specialty pharmacy services on quality of life in the plaque psoriasis population.
  • CPS health system specialty pharmacy (HSSP) staff collect and monitor DLQI scores which are then used in conjunction with other physical tests to determine if therapy is appropriate and dermatologic conditions are improving.

Objectives

The primary objective of this study is to assess the impact of HSSP services on DLQI scores in patients receiving treatment for plaque psoriasis.

 

Read about the team's findings by downloading the Outcomes Study below.

 

Download the abstract:

Related Posts

 

Submit your contact information below to receive insights from our team of pharmacy solutions experts.